Europe Throat Cancer Diagnostics Market, By Product Type (Instruments and Consumables & Accessories), Test Type (Imaging Test, Blood Test, Biopsy, and Others), Cancer Type (Pharyngeal Cancer and Laryngeal Cancer), Stages (Stage 0, Stage I, Stage II, Stage III and Stage IV), Age Group (30-65, 65 and above, 21-29 and Below 21), End User (Hospitals, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centres, Cancer Research Institutes and Others), Distribution Channel (Direct Tender and Retail Sales) - Industry Trends and Forecast to 2030.
Europe Throat Cancer Diagnostics Market
Increasing awareness about throat cancer has enhanced the market demand. The rising healthcare expenditure for better health services also contributes to the market's growth. The major market players focus on various service launches and approvals during this crucial period.
Europe throat cancer diagnostics market is expected to grow in the forecast period of 2023 to 2030. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.7% in the forecast period of 2023 to 2030 and is expected to reach USD 721.95 million by 2030 from USD 429.94 million in 2022.
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customisable to 2020-2015)
|
|
Quantitative Units
|
Revenue in USD Million
|
|
Segments Covered
|
By Product Type (Instruments and Consumables & Accessories), Test Type (Imaging Test, Blood Test, Biopsy, and Others), Cancer Type (Pharyngeal Cancer and Laryngeal Cancer), Stages (Stage 0, Stage I, Stage II, Stage III and Stage IV), Age Group (30-65, 65 and above, 21-29 and Below 21), End User (Hospitals, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centres, Cancer Research Institutes and Others), Distribution Channel (Direct Tender and Retail Sales)
|
|
Countries Covered
|
Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Rest of Europe
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd., FUJIFILM Corporation, Thermo Fisher Scientific Inc., CANON MEDICAL SYSTEMS CORPORATION, Koninklijke Philips N.V., Merck KGaA, BD, General Electric Company, Illumina, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Abbott, QIAGEN, Siemens Healthcare GmbH, Myriad Genetics Inc., Quest Diagnostics Incorporated, Hologic, FONAR Corp., Medonica Co. LTD, SternMed GmbH, MinFound Medical Systems Co., Ltd, and PlexBio among others
|
Market Definition
Throat cancer is a type of cancer that forms in tissues of the pharynx (the hollow tube inside the neck that starts behind the nose and ends at the top of the windpipe and esophagus). Throat cancer includes cancer of the nasopharynx (the upper part of the throat behind the nose), the oropharynx (the middle part of the pharynx), and the hypopharynx (the bottom part of the pharynx). Cancer of the larynx (voice box) may also be included as a type of throat cancer. Most throat cancers are squamous cell carcinomas (cancer that begins in thin, flat cells that look like fish scales), also called pharyngeal cancer.
Europe Throat Cancer Diagnostics Market Dynamics
Drivers
- Growing prevalence of throat cancer
Throat cancer is the second most common type of leukemia diagnosed in adults and children, but most cases occur in adults. Although it can be diagnosed at any age, it is uncommon before age 45. The average age of diagnosis is age 68. The rising use of cigarettes and other tobacco substitutes may be partially responsible for the rise in the prevalence of throat cancer.
People affected with throat cancer can see the symptoms such as a cough, changes in their voice, such as hoarseness or not speaking clearly, difficulty swallowing, ear pain, a lump or sore that doesn't heal, a sore throat, and weight loss among others.
- Novel technological advancements in throat cancer diagnostics
Radiotherapy has an integral role in the treatment of throat cancer. Although radiotherapy has the potential to cure patients with advanced diseases, it also carries the potential for significant long-term morbidity. New technologies in the setting of head and neck radiotherapy are emerging, which have the potential to increase the cure rate and decrease toxicity. These new technologies include improved radiotherapy treatment design (intensity-modulated radiation therapy) and improved planning and implementation (image-guided radiation therapy).
Restraints
- Late diagnosis and poor prognosis of throat cancer
Cancer is the leading cause of death worldwide. By 2030, it is anticipated that there will be 13.1 million more cancer-related deaths per year. However, if they are identified early on and given the right care, some cancers can be cured. The diagnostic process may experience delays in cancer diagnosis. When patients overlook or fail to respond to potentially cancerous signs, the late patient diagnosis will lead to the growth of cancerous tissue, worsening the cancer condition. The main cause of delayed presentation is a lack of public knowledge of early cancer signs, especially if such symptoms are unusual.
Thus, the late diagnosis often results from these factors, which result in poor prognosis. Thus, these are expected to restrain the growth of the Europe throat cancer diagnostics market.
High cost for the installation of diagnostic devices
Cancer diagnostics have become increasingly expensive due to the growing number of throat cancer patients and the rising prices of medical devices. The modern technological devices used in cancer diagnosis also play a significant role in the high prices of cancer diagnostics, providing a definitive diagnosis for cancer in thyroid nodules with high accuracy. Therefore, the high cost of diagnostics procedures for throat cancers is hampering the market's growth.
The diagnostic products or devices which are used in the detection of cancer are becoming advanced. However, the procedure for cancer diagnostics is also costly, which hampers the growth of the throat cancer diagnostics market because the devices used in the process of cancer diagnosis are getting more expensive for the early detection of cancerous tissue, which results in to increase in the cost of diagnostics procedure.
Opportunities
- Rise in healthcare expenditure for cancer diagnosis and treatment
Across the globe, research and development activities are escalating owing to the public health expenditure with economic performances. Rising healthcare expenditure could result in better provision of research and development opportunities. It is anticipated to increase the demand for throat diagnostics. Increasing the healthcare expenditure for cancer treatment also helps the patient take hassle-free advanced diagnostics and treatment for fast recovery. The spending on healthcare is made up of the combination of out-of-pocket payments (people paying for their care), government expenditure, and various sources such as different healthcare schemes published by the government in different regions. It also includes health insurance and activities by non-governmental organizations. This increasing healthcare expenditure for cancer treatment is an opportunity for the market's demand.
- Government initiatives toward cancer diagnostics
The government plays a major role while taking the initiative for cancer diseases because cancer is a leading disease worldwide. Throat cancer has increased very rapidly in individuals in past decades. Throat cancer is the most prevalent cancer, with estimated 410,376 people new cases in 2022, according to cancer.gov.
There are several initiatives taken by the government that helps boost the market's demand, and these initiatives will increase awareness among people regarding their health and take early diagnosis for better cure and precaution. Growing healthcare expenditure is also beneficial for further economic growth and healthcare sector growth, and it is primarily fruitful as it significantly affects the development of better and advanced therapeutic options with various diagnostics products.
Challenges
- Increased cost, safety, and convenience issues
Throat cancer is fatal, and the diagnosis process of this type of cancer also has safety issues. It is also not cost-effective. One of the most costly medical disorders to treat globally is cancer. Cancer patients may be hospitalized and receive a variety of therapies, such as surgery, radiation therapy, and systemic therapy. Health insurance premiums for cancer patients are now more expensive than in the past. In addition, their co-payment, deductible, and coinsurance costs are rising.
Rising helium shortage and rising risk of excessive radiation exposure are projected to restrict the use of CT scanners, threatening the possibilities of rising capital investments and low benefit-cost ratio for biomarkers. Many hospitals in developing countries cannot invest in diagnostic imaging equipment, which has led to increased use of reconstructed diagnostic imaging due to high expenditures and financial restrictions.
Recent Developments
- In August 2022, F. Hoffmann-La Roche Ltd, announced the launch of the Digital LightCycler System, Roche's first digital polymerase chain reaction (PCR) system. This next-generation system detects disease and is designed to accurately quantify trace amounts of specific DNA and RNA targets not typically detectable by conventional PCR methods. This has helped the company to increase its Europe presence in the market
- In March 2021, Hologic, Inc. announced that the company had acquired Diagenode, a privately held Globalan developer and manufacturer of molecular diagnostic assays and epigenetics products. This further strengthens the molecular diagnostics business in the Europe market
Europe Throat Cancer Diagnostics Market Scope
The Europe throat cancer diagnostics market is segmented into product type, test type, cancer type, stages, age group, end user, and distribution channel. The growth amongst these segments will help you analyse meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Product Type
- Instruments
- Consumables & accessories
On the basis of product type, the Europe throat cancer diagnostics market is segmented into instruments and consumables & accessories.
Test Type
- Imaging Test
- Blood Test
- Biopsy
- Others
On the basis of test type, the Europe throat cancer diagnostics market is segmented into imaging test, blood test, biopsy, and others.
Cancer Type
- Pharyngeal cancer
- Laryngeal cancer
On the basis of cancer type, the Europe throat cancer diagnostics market is segmented into pharyngeal cancer and laryngeal cancer.
Stages
- Stage 0
- Stage I
- Stage II
- Stage III
- Stage IV
On the basis of stages, the Europe throat cancer diagnostics market is segmented into stage 0, stage I, stage II, stage III, and stage IV.
Age Group
- 30-65
- 65 and above
- 21-29
- Below 21
On the basis of age group, the Europe throat cancer diagnostics market is segmented into 30-65, 65 and above, 21-29, and below 21.
End User
- Hospitals
- Associated labs
- Independent diagnostic laboratories
- Diagnostic imaging centers
- Cancer research institutes
- Others
On the basis of end user, the Europe throat cancer diagnostics market is segmented into hospitals, associated labs, independent diagnostic laboratories, diagnostic imaging centers, cancer research institutes, and others.
Distribution Channel
- Direct tender
- Retail sales
On the basis of distribution channel, the Europe throat cancer diagnostics market is segmented into direct tender and retail sales.
Europe Throat Cancer Diagnostics Market Regional Analysis/Insights
The Europe throat cancer diagnostics market is analysed, and market size insights and trends are provided by country, product type, test type, cancer type, stages, age group, end user, and distribution channel, as referenced above.
The countries covered in this market report are Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, the rest of Europe.
Germany is expected to dominate the Europe throat cancer diagnostics market due to the rising incidence and prevalence of throat nodules and cancer.
The country section of the report also provides individual market impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of Europe brands and their challenges faced due to competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Europe Throat Cancer Diagnostics Market Share Analysis
The Europe throat cancer diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Europe presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to Europe throat cancer diagnostics market.
Some of the major players operating in the Europe throat cancer diagnostics market are F. Hoffmann-La Roche Ltd., Abbott., Illumina, QIAGEN, Thermo Fisher Scientific Inc., Quest Diagnostics Incorporated, Inc. Merck KGaA., Hologic, Inc., General Electric Company, Siemens Healthcare GmbH, B.D, Myriad Genetics, Inc., Diasorin S.P.A, Koninklijke Philips N.V., Beijing O&D Biotech Co., Ltd, PlexBio Co, Ltd., FUJIFILM Corporation, Canon Inc., FONAR Corp., Medonica Co. LTD, MinFound Medical Systems Co, Sternmed Gmbh, Time Medical Holding., Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., among others.
SKU-